Here, a first attempt was made using a recently developed in vitro 3D infection platform that employs hepatic cell line-derived spheroids to generate an effective average concentration (Cav) of M5717, a new anti-malarial that acts as a Plasmodium elongation factor 2 inhibitor, which is also active against the liver stage of infection. Here, EEF2 is linked to infection.